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http://dx.doi.org/10.1016/j.jmii.2012Background: Avian H5N1 influenza has caused human infections globally and has a high
mortality rate. Rapid production of effective vaccines is needed.
Methods: A phase 1, randomized, observer-blinded clinical trial was conducted to examine the
safety and immunogenicity of an inactivated whole virion vaccine against the influenza A/H5N1
virus produced from the Madin-Darby canine kidney (MDCK) cell line. Participants were random-
ized to four groups and administered two intramuscular doses of vaccine containing 3 mg
hemagglutinin (HA), 3 mg HA with 300 mg aluminum phosphate (AlPO4), 6 mg HA, and 6 mg HA
with 300 mg AlPO4, respectively, at two visits, 21 days apart. Serum hemagglutination inhibition
(HAI) and neutralizing antibody levels were determined at baseline and on Days 21 and 42.
Results: Sixty healthy individuals were enrolled. The neutralization assay showed a significant
immune response in the 6 mg with ALPO4 group on Day 42 compared to pre-vaccination levels
(11.32  9.77 vs. 4.00  0, pZ 0.02). The adjuvant effect in neutralization assay was also
significant on Day 42 in the 6 mg group (4.52 1.94 without adjuvant vs. 11.32 9.77 with adju-
vant, pZ 0.02). HAI assay also showed an aluminum adjuvant-induced increasing trend in HAI
geometric mean titer on Day 42 in the 3 mg and 6 mg groups (6.02 versus 8.20, pZ 0.05 and 5.74
versus 8.21, pZ 0.14). The most frequent adverse event was local pain (20% to 60%). There
were no vaccine-related severe adverse effects.of Internal Medicine, National Taiwan University Hospital, #7 Chung-Shan South Road, Taipei 100,
com (S.-M. Hsieh).
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Phase I study of MDCK cell line H5N1 vaccine 449Conclusion: MDCK cell line-derived H5N1 vaccine was well tolerated. It is necessary to investi-
gate further the immunogenicity of higher antigen doses and the role of aluminum adjuvant in
augmenting the effect of the vaccine.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Avian H5N1 influenza has been infecting humans globally
since 1997 and has a high mortality rate. According to the
bulletin issued by the World Health Organization, 607
human infections and 358 deaths have been attributed to
H5N1 infection up to July 2012 in Africa, Asia, and Europe.1
Experts warn that the next influenza pandemic is imminent
and could be severe. Prevention and control will depend on
the rapid production and worldwide distribution of specific
pandemic influenza candidate vaccines.
A number of challenges havebeenencountered during the
preparation of pandemic influenza vaccines. Firstly, timely
isolation of the strain and mass production are very impor-
tant; secondly, a two-dose vaccination protocol has been
recommended in order to achieve protective antibody levels
in immunologically naive vaccine recipients.2e5 Rapid
production of adequate amounts of H5N1 HA antigen for
vaccination preparation is therefore an important challenge.
Although the HA antigen has been traditionally produced
in eggs, an H5N1 influenza vaccine was recently success-
fully produced from whole virus grown in Madin-Darby
canine kidney (MDCK) cells.6 This approach used a contin-
uous cell line production for the rapid supply for HA antigen
and circumvented the risk of shortage of egg-culture
derived vaccine during avian influenza epidemics.7,8
MDCK-derived purified inactivated H5N1 vaccine antigens
were safe and induced immune responses in animal
studies.6 Moreover, formulation with adjuvants such as
aluminum phosphate elicited a stronger response in
animals, even at low doses.9 However, it is necessary to
evaluate the safety and immunogenicity of these vaccines
in human studies. In this human Phase I clinical study, we
evaluated the safety and immunogenicity of nonadjuvant
and alum formulated H5N1 virion influenza vaccine derived
from MDCK cells.
Materials and methods
Study design
The main objective of this prospective, randomized, open
label, observer-blind, single-center study, was to evaluate
the safety, reactogenicity and humoral immune responses
to inactivated H5N1 influenza virion vaccines, either in the
nonadjuvanted form or formulated with aluminum phos-
phate (AlPO4). The study recruited a total of 60 healthy
individuals at the National Taiwan University Hospital
between November 25, 2009 and January 7, 2011. Study
participants were randomized to 4 groups, as follows:
Group I received 3 mg haemagglutinin (HA); Group II
received 3 mg HA with adjuvant (300 mg AlPO4); Group IIIreceived 6 mg HA; and Group IV received 6 mg HA with
adjuvant (300 mg AlPO4). The participants were adminis-
tered two doses of 0.5 ml H5N1 vaccine, on Days 0 and 21.
Recruitment of study participants was carried out in two
parts. In Part 1, the initial 12 participants were sequentially
enrolled and randomized to three blocks; Block A, Block B
and Block C. The first four participants of Block A received
two doses of vaccination, 21 days apart, and local/systemic
reactions and adverse events were recorded after each
vaccination. Block B participants were then enrolled and
received their vaccinations 7 days after Block A participants
had received their second vaccine. Block C participants
were enrolled and received their vaccinations 7 days after
the Block B participants had received their second vaccine.
The safety data and adverse events (recorded on diary
cards) were reviewed after vaccine administration. After it
was determined that there were no safety concerns with
the vaccine, the rest of the study participants (48 partici-
pants) were recruited in Part 2 of the study.
The study followed the principles of the Declaration of
Helsinki, Good Clinical Practice (as defined by the Inter-
national Conference on Harmonisation), and Taiwanese
regulatory requirements. The study protocol was approved
by the human research ethics committee in National Taiwan
University Hospital and all study participants provided
written informed consent.Participants
This study recruited healthy male and female individuals
(age 20 and 60 years at the time of enrolment). The
female participants were: (1) of nonchildbearing potential,
i.e. surgically sterilized (defined as having undergone
hysterectomy and/or bilateral oophorectomy and/or bilat-
eral salpingectomy); (2) 1 year postmenopausal; or (3) had
agreed to practice abstinence or use adequate contracep-
tive precautions for 30 days prior to the study and for 2
months after study completion. Female participants were
also required to have a negative pregnancy test and to not
be breastfeeding for the duration of the study.
Exclusion criteria included: (1) previous known or
potential exposure to avian influenza virus or any adju-
vanted or unadjuvanted H5N1 HA antigen vaccine; (2)
vaccination with any influenza vaccine within 6 months
prior to study enrolment or at any time during the study
period; (3) presence of confirmed or suspected abnormal
immune function, immunosuppressive, or immunodeficient
condition, including human immunodeficiency virus infec-
tion; (4) history of hypersensitivity to vaccines or a history
of allergic disease or reactions likely to be exacerbated by
any component of the vaccine; (5) chronic administration
(defined as >14 days) of immunosuppressants or other
450 S.-C. Pan et al.immune-modifying drugs within 6 months prior to the
administration of the study vaccine (corticosteroids,
including prednisone or equivalent,  0.5 mg/kg/day;
inhaled and topical steroids were allowed); (6) presence of
any medical illness including clinically significant acute
pulmonary, cardiovascular, hepatic, or renal functional
abnormality, as determined by physical examination or
laboratory screening tests; (7) administration of immuno-
globulins and/or any blood products within the three
months preceding the administration of the study vaccine
or at any time during the study; (8) presence of acute
disease at the time of enrolment (defined as the presence
of a moderate or severe illness with or without fever/oral
temperature 37.5C); (9) presence of a fever (oral
temperature 37.5C) at the time of enrolment; (10)
aspartate aminotransferase, alanine aminotransferase, or
serum creatinine 1.5 times upper limit normal value; (11)
complete blood count deemed unsuitable for vaccination
by investigator; (12) chronic or long-term use of acetylsa-
licylic acid medication; (13) participation in other clinical
studies of investigational drugs within 3 months prior to the
start of the present study; or (14) participation in other
clinical studies of investigational vaccines within 6 months
prior to the start of this study.
Vaccine
The monovalent vaccine seed virus was an H5N1 reassortant
reference virus (A/Vietnam/1194/2004, NIBRG-14) derived
by reverse genetics from the highly pathogenic avian strain
A/Vietnam/1194/2004 (wild type) by the UK National
Institute for Biological Standards and Control. The seed
virus was cultivated in eggs for 4 generations at the Centers
for Diseases Control, Taiwan, and then transferred to the
Vaccine Research and Development Center of the National
Health Research Institution, Taiwan for a further 5-passage
adaptation in MDCK cells. MDCK-grown, sucrose-gradient
purified, and formaldehyde-inactivated whole virus candi-
date vaccine was developed and produced by Vaccine
Research and Development Center.6,9
The study vaccine containing inactivated whole influ-
enza virus and 0.01% formaldehyde, was formulated in
phosphate buffered saline (PBS). The vaccine (7 mL liquid/
vial) was produced as a multidose formula in 20 mL vials
(0.5 mL/dose, total 14 doses/vial; each vial applied to 10
participants). Different formulations of the vaccine were
made using two different strengths of HA protein, in non-
adjuvant or AlPO4 formulated. All vaccines to be adminis-
trated to participants were stored at the defined
temperature range (þ2C to þ8C) in a safe and locked
place. The storage unit was monitored by a continuous
temperature monitoring device.
Formulated vaccine, in a volume of 0.5 ml as a single
dose, was withdrawn for administration to the participants.
Intramuscular administration of the vaccine was done in the
deltoid region of the nondominant arm.
Safety
All study participants were monitored for self-reported as
well as investigator-assessed local and general adverseevents during the 6 weeks following the first vaccination.
Complete blood count, serum biochemistry, adverse
events, and serious adverse events (SAEs) were evaluated.
Immunogenicity
Serum samples were obtained prior to vaccination, as well
as on Days 21 and 42 after vaccination. Antibody titers were
measured by hemagglutination-inhibition (HAI) assays and
virus neutralization assays. Based on international guide-
lines, three immunogenicity end-points were applied to
evaluate the different formulations of the influenza
vaccines.10,11 These included: (1) the seroprotective rate
(the proportion of participants with antibody level 1:40 on
HAI assay); (2) the seroconversion rate (the proportion of
participants with a prevaccination HAI antibody titer <1:10
and a post-vaccination titer 1:40, or a prevaccination titer
1:10 and an increase in the titer by a factor of four or
more); and (3) evaluation of the geometric mean titers
(GMT) of the HAI antibody titer.
Microneutralization assays were performed according to
previous reports.6,9 Thawed human serum samples were
used without further treatment in the assay. Each serum
was tested in quadruplicate.
Statistical analyses
To compare the characteristics between the four dosing
groups, the ANOVA test was applied for continuous vari-
ables and Fisher’s exact test was used for categorical
variables. Wilcoxon rank sum test was applied for the
comparison between either 2 dosing groups for continuous
variables and fisher’s exact test for categorical variables.
Wilcoxon signed rank test was used for comparison again
the pre-post vaccination level of titers. The seroprotection
and the seroconversion rates were summarized by rate and
95% confidence intervals. The 95% confidence intervals of
the geometric mean titers were obtained by taking anti-log
for the statistics of the log titer. All statistical analyses
were performed by SAS software version 9.2 (SAS, Cary, NC,
USA) and all tests were two-sided when applied. Statistical
significance for all comparisons was determined at
p< 0.05.
Results
Study participants
Of the 61 adult individuals recruited in this study, one had
elevated liver function markers (defined as aspartate
aminotransferase or alanine aminotransferase 1.5 times
the upper limit normal value) prior to the study and was
therefore excluded. The remaining 60 participants were
randomly divided into 4 groups as described in Fig. 1. The
demographic characteristics of all vaccinated participants
are summarized in Table 1. Of the two participants who did
not receive the second dose of the vaccine, one failed to
come in within the acceptable time window for the second
dose and the second had elevated liver function tests after
the first dose of the vaccine. These two participants were
Figure 1. Enrollment and follow up of the study participants. *One participant was excluded from immunogenicity analysis, even
though they received two doses of vaccination, due to receiving another investigational vaccine.
Phase I study of MDCK cell line H5N1 vaccine 451therefore excluded from the immunogenicity analysis. A
third participant received a second investigational vaccine
125 days after the second dose of vaccine in our study and
was therefore also excluded from the immunogenicity
analysis. Our safety analyses therefore included a total of
60 participants, while the immunogenicity analyses
included 57 participants.
Safety
Table 2 summarizes the injection-site and systemic reac-
tions that occurred during the 7 days following each
vaccination. Our data showed that 38 participants (32.2%)
had at least one solicited local event, while 30 participants
(25.4%) had at least one solicited systemic event. The most
frequently reported symptom among all the groups wasTable 1 Demographic characters of all vaccinated participants
3 mg HA
nZ 15
3 mg HA with
nZ 15
Sex, no (%)
Male 3 (20.0%) 4 (26.7%)
Female 12 (80.0%) 11 (73.3%)
Age, years
Mean SD 32.0 7.5 29.4 8.8
Range 20.2e47.3 20.1e48.8
Race, no (%)
Chinese 15 (100.0%) 15 (100.0%)
Asian, other than Chinese 0 (0.0%) 0 (0.0%)
Medical history, no (%)
Yes 10 (66.7%) 5 (33.3%)
No 5 (33.3%) 10 (66.7%)
Concomitant medication
Yes 5 (33.3%) 3 (20.0%)
No 10 (66.7%) 12 (80.0%)
AlPO4: aluminum phosphate; HAZ hemagglutinin.local pain (20% to 60%). Symptoms remained mostly mild to
moderate in intensity and resolved rapidly. The groups
receiving adjuvanted vaccines did not have a significantly
higher occurrence of solicited symptoms. We also found no
antigen-dose effect on the reactogenicity of the candidate
vaccine.
Data showed that 35 participants (29.7%) reported
unsolicited adverse events after administration of vacci-
nation. The most common reported unsolicited events
included upper respiratory tract infection in 6 participants
(5%) and dizziness in 8 (6.7%). Five participants had
elevated liver function test after the first dose of vaccina-
tion and 2 after the second dose of vaccination. The
intensity of abnormal liver function was mild to moderate.
One participant developed hyperbilirubinemia after the
first dose (total bilirubin was elevated from 1.5 mg/dL toAlPO4 6 mg HA
nZ 15
6 mg HA with AlPO4
nZ 15
P value
0.54
4 (26.7%) 7 (46.7%)
11 (73.3%) 8 (53.3%)
0.66
28.5 10.9 28.7 6.5
20.1e48.9 20.4e42.0
1.00
15 (100.0%) 14 (93.3%)
0 (0.0%) 1 (6.7%)
0.07
11 (73.3%) 11 (73.3%)
4 (26.7%) 4 (26.7%)
0.24
8 (53.3%) 7 (46.7%)
7 (46.7%) 8 (53.3%)
Table 2 Proportion of participants having a solicited local
or systemic event within 7 days after each vaccination
3 mg HA 3 mg HA
with AlPO4
6 mg HA 6 mg HA
with AlPO4
First dose nZ 15 nZ 15 nZ 15 nZ 15
Any solicited
local event
3 (20.0%) 6 (40.0%) 6 (40.0%) 9 (60.0%)
Hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Pain 3 (20.0%) 6 (40.0%) 6 (40.0%) 9 (60.0%)
Redness 1 (6.7%) 3 (20.0%) 0 (0.0%) 1 (6.7%)
Swelling 1 (6.7%) 2 (13.3%) 1 (6.7%) 0 (0.0%)
Second dose nZ 15 nZ 15 nZ 15 nZ 13
Any solicited
local event
4 (26.7%) 4 (26.7%) 4 (26.7%) 2 (15.4%)
Hematoma 1 (6.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Pain 4 (26.7%) 4 (26.7%) 4 (26.7%) 2 (15.4%)
Redness 1 (6.7%) 2 (13.3%) 0 (0.0%) 0 (0.0%)
Swelling 1 (6.7%) 0 (0.0%) 1 (6.7%) 0 (0.0%)
First dose nZ 15 nZ 15 nZ 15 nZ 15
Any solicited
systemic event
4 (26.7%) 3 (20.0%) 3 (20.0%) 5 (33.3%)
Fatigue 2 (13.3%) 2 (13.3%) 2 (13.3%) 3 (20.0%)
Fever 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (6.7%)
Headache 2 (13.3%) 0 (0.0%) 2 (13.3%) 1 (6.7%)
Joint pain 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Muscle ache 3 (20.0%) 2 (13.3%) 2 (13.3%) 4 (26.7%)
Shivering 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Second dose nZ 15 nZ 15 nZ 15 nZ 13
Any solicited
systemic event
5 (33.3%) 4 (26.7%) 4 (26.7%) 2 (15.4%)
Fatigue 3 (20.0%) 2 (13.3%) 2 (13.3%) 1 (7.7%)
Fever 1 (6.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Headache 3 (20.0%) 2 (13.3%) 1 (6.7%) 0 (0.0%)
Joint pain 0 (0.0%) 0 (0.0%) 1 (6.7%) 0 (0.0%)
Muscle ache 2 (13.3%) 1 (6.7%) 1 (6.7%) 1 (7.7%)
Shivering 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
452 S.-C. Pan et al.2.0 mg/dL 21 days after the first dose) and therefore did
not receive the second dose of vaccination. There were no
deaths reported before the release of this report. There
were also no SAEs during the study period.
Immunogenicity assessment
HAI assays and neutralization assays were used to measure
the humoral immune response against the vaccine strain.
Immunogenicity data were also evaluated in the pre-
protocol cohort.
HAI assays
Prior to the vaccination, none of the study participants had
protective antibody titers (1:40). There was no significant
difference in the seroprotection rate between the groups at
21 days and 42 days after the vaccination (Table 3).
There was also no significant difference in the serocon-
version rate between the different dosing groups. Theseroconversion rate among all study participants was 4/57
(7.0%) on Day 21 (after the first vaccination) and 5/57
(8.8%) on Day 42 (after the second vaccination).
The HAI GMT and the mean fold rise against H5N1 virus
are summarized in Table 3. There was no significant
increase in the mean fold increase of GMT in the 4 groups at
21 days and 42 days after vaccination. There was also no
significant dosing response. However, there was a trend of
higher HAI GMT in groups that received adjuvant compared
to groups that did not receive adjuvant at 42 days after
vaccination, both in the 3 mg group (pZ 0.05) and 6 mg
group (pZ 0.14).
Neutralization assays
One sample from the participant in the 6 mg group was
retested and defined as an outlier, based on the laboratory
data (neutralization assay was 126.49 on Day 42 while the
mean was 12.65 31.55) and was therefore excluded from
the neutralization assay. Of the remaining 56 cases
analyzed, there was a significant increase in neutralization
assay values in the 6 mg with ALPO4 group on Day 42
compared to pre-vaccination values (11.32 9.77 vs.
4.00 0, pZ 0.02). An adjuvant effect was also noted in
the 6 mg group on Day 42 (4.52 1.94 without adjuvant vs.
11.32 9.77 with adjuvant, pZ 0.02; Table 3).
Discussion
In this study, we showed that the candidate H5N1 vaccine
from MDCK cell line was well tolerated and no SAEs were
noted at the dosing range used. Results from the neutrali-
zation assay showed a significant immune response in the
6 mg with adjuvant group, while no significant response was
noted in the seroprotection rate, seroconversion rate and
HAI GMT. The neutralization assay also showed an adjuvant
effect with ALPO4 in the 6 mg group, and this trend was also
noted in the HAI GMT in the 3 mg as well as 6 mg groups.
Vaccination has been shown to be the major pathway to
preventing influenza epidemics. However, in the case of
novel influenza strains such as H5N1, vaccine production
faces the challenges as timely requirement for strain
isolation and mass production for the mostly naı¨ve pop-
ulation. The traditional egg-based culture vaccine
manufacturing methods, which are labour-intensive and
lack flexibility, may therefore be inadequate to meet
production demands in an influenza pandemic. Importantly,
in an avian pandemic, the supply of embryonated eggs may
be threatened, since avian influenza also infects egg-
producing poultry.
There has been a recent focus on strategies for egg-
independent vaccine production. Reverse genetics-based
methods have been used to create attenuated strains by
removing the polybasic amino acid sequence responsible
for virulence. However, the antigen yield from reverse
genetics-derived H5N1 viruses constituted only 30% to 40%
of the average of seasonal influenza viruses.12 Vaccine
production based on cell cultures has shown promise and
offers the advantage of flexibility for rapid scale-up,
reduced risk for contamination in closed scalable bioreac-
tors, and does not depend upon a supply of embryonated
Table 3 Immune response among participants receiving different dose, with/without adjuvant of study vaccine
(a)3 mg HA
nZ 15
(b)3 mg þ AlPO4
nZ 14
pa (c)6 mg HA
nZ 15
(d)6 mg þ AlPO4
nZ 13
pb
HAI seroprotection
(titer ‡1:40) % (95% CI)
Prevaccination 0.00% (0.00%, 0.00%) 0.00% (0.00%, 0.00%) d 0.00% (0.00%, 0.00%) 0.00% (0.00%, 0.00%) d
21 days 0.00% (0.00%, 0.00%) 7.14% (0.18%, 33.87%) 0.48 6.67% (0.17%, 31.95%) 15.38% (1.92%, 45.45%) 0.58
42 days 6.67% (0.17%, 31.95%) 7.14% (0.18%, 33.87%) 1.00 6.67% (0.17%, 31.95%) 15.38% (1.92%, 45.45%) 0.58
HAI seroconversion
rate (%) (95% CI)
21 days 0.00% (0.00%, 0.00%) 7.14% (0.18%, 33.87%) 0.48 6.67% (0.17%, 31.95%) 15.38% (1.92%, 45.45%) 0.58
42 days 6.67% (0.17%, 31.95%) 7.14% (0.18%, 33.87%) 1.00 6.67% (0.17%, 31.95%) 15.38% (1.92%, 45.45%) 0.58
HAI geometric mean
titer (95% CI)
Prevaccination 5 (5.00, 5.00) 5 (5.00, 5.00) 1.00 5 (5.00, 5.00) 5 (5.00, 5.00) 1.00
21 days 5 (5.00, 5.00) 6.10 (3.97,9.35) 0.34 5.74 (4.27,7.73) 6.89 (4.30,11.04) 0.50
42 days 6.02 (4.05, 8.94) 8.20 (5.20, 12.94) 0.05 5.74 (4.27, 7.73) 8.52 (5.08, 14.30) 0.14
(a)3 mg HA
nZ 15
(b)3 þ AlPO4
nZ 14
pa (c)6 mg HA
nZ 14c
(d)6 þ AlPO4
nZ 13
pb
Neutralization
assays (95% CI)
Prevaccination 6.02 6.12 (2.63, 9.41) 4.52 1.94 (3.40, 5.64) 0.60 4.00 0 (4.00, 4.00) 4.00 0 (4.00, 4.00) 1.00
21 days 6.57 8.60 (1.81, 11.34) 5.45 3.04 (3.70, 7.20) 0.65 4.38 1.43 (3.56, 5.21) 8.28 11.35 (1.42, 15.13) 0.24
42 days 6.43 7.36 (2.35, 10.50) 8.64 8.32 (3.83, 13.44) 0.36 4.52 1.94 (3.40, 5.64) 11.32 9.77 (5.41, 17.23) 0.02
Neutralization assays
geometric mean titer (95% CI)
Prevaccination 2.67 (1.73,4.11) 2.38 (1.80, 3.15) 1.00 2.00 (2.00, 2.00) 2.00 (2.00, 2.00) 1.00
21 days 2.69 (1.70, 4.26) 2.86 (1.89, 4.32) 0.65 2.47 (1.89, 3.21) 3.32 (1.80, 6.12) 0.72
42 days 2.72 (1.72, 4.31) 4.01 (2.18, 7.40) 0.22 2.38 (1.80, 3.15) 6.03 (3.05, 11.92) 0.03
a p value comparing the 3 mg with 3 mg with ALPO4 group.
b p value comparing the 6 mg with 6 mg with ALPO4 group.
c One case was excluded since outliner data in 6 mg group on Day 42.
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454 S.-C. Pan et al.eggs.13 There are currently a number of licensed pandemic
and seasonal influenza vaccines, produced in Vero and
MDCK cell lines.14e16 There have also been Phase 1/2 clin-
ical trials of two Vero cell line-derived, and one MDCK cell
line-derived H5N1 vaccines.14,17,18 The safety profile of our
candidate vaccine is comparable with the other cell line-
derived H5N1 vaccines. The most frequently local side
effect reported by our study population was pain (20% to
60%), which was comparable with data from other cell line-
derived H5N1 vaccines.14,17,18 The individual who had mild
to moderate elevation of bilirubin level after the first dose
of vaccination, did not receive the second dose and had
stable bilirubin level after follow-up on Day 210. There
were also no SAEs among our study patients, suggesting that
our candidate H5N1 vaccine was well tolerated.
In addition to optimizing the manufacturing method,
another way to reduce the demand of target antigen is to
optimize the immune response. Although adequate immune
responses to unadjuvanted split H5N1 vaccines required
formulations containing up to 90 mg HA, the use of classical
aluminum-based adjuvants was shown to decrease this to
30 mg to 45 mg/dose.4,17e20 Our data were comparable with
these studies and showed that aluminum-based adjuvants
played a significant role in enhancing the immune response
in the 6 mg group on Day 42. The trend was also noted in the
HAI GMT in the 3 mg group as well as in the 6 mg group.
Interestingly, these data differed from those from other
cell line-derived H5N1 vaccines, where addition of the
aluminum adjuvant did not improve, or decreased, the
immune response at an antigen dose of 7.5 mg to 15 mg.14,17
The conflicting effects of aluminum adjuvant on H5N1
vaccines may be explained by the fact that, in addition to
the antigen concentration, the immune enhancing effect of
the adjuvant may also be dictated by the adjuvant to
antigen ratio.21 MF59 has also been used as an adjuvant and
the 3.75 mg H5N1 vaccine containing 50% MF59 was shown to
generate a protective immune response, which fulfilled the
European criteria for pandemic vaccine licensure.18
Another oil-in-water emulsion adjuvant formulation as
ASO3A had been used in split-virion H5N1 influenza vaccine
and showed protective immune response and also adjuvant
effect.22 Further studies are needed to explore the role of
aluminum and other adjuvants in cell line derived-H5N1
vaccines.
We evaluated the neutralization assay as a tool to
measure immunogenicity of the vaccine. The HAI assay is
not the most efficient method to detect anti-H5 antibodies
in avian virus infections,23e25 and the neutralization assay
was previously suggested as a better method to evaluate
the immune response in an animal model26 and in a human
study.27 Our data are consistent with these studies and
suggested that the neutralization assay was a more sensi-
tive means of evaluating the immune response. It has been
suggested that among criteria to test influenza vaccine
during manufacture is to confirm sero-conversion with
neutralization titers>1:40 after two shots of different
doses of vaccine.26 Whether such new criteria should be
included in further avian influenza vaccine manufacture
needs further validation.
In conclusion, our study demonstrated that the H5N1
vaccine produced from the MDCK cell line can be used as
a safe alternative to the traditional H5N1 vaccinepreparation. Our neutralization assays showed a significant
immune response in participants vaccinated with the 6 mg
dose with alum adjuvant. It is important to further inves-
tigate the possibility of enhancing vaccine immunogenicity
with higher antigen doses and to evaluate the role of
aluminum or other nonalum adjuvants in vaccine
formulations.Acknowledgments
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